No abstract

Outpatient costs represented 82% of total costs (antineoplastics 26%, supportive care 15%, office visits 4%, labs/diagnostics 1%, radiation/surgery 1%, other drugs 19%, procedures 15%). Inpatient costs (emergency department [ED] visits/hospitalizations) represented 18% of total cost for patients with inpatient claims; mean total cost (N= 3552, 67%) was $119,034. ConClusions: The study shows high TCC for advanced NSCLC; with increasing costs in later LOTs. Nearly 70% of patients had ED visits/hospitalizations; inpatients incurred higher total costs. Novel therapies may potentially impact TCC by influencing outpatient and inpatient costs.